Oculis and EURETINA Announces the Ramin Tadayoni Award
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial With Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease With a Precision Medicine Strategy
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to Its Board of Directors and Scientific Advisory Board
6-K: Report of foreign private issuer (related to financial reporting)
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
Oculis to Present at Bank of America Global Healthcare Conference